Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity

Phase 2positiveEnicepatidePositive

AI Analysis

Summary

Genentech announced positive Phase II results for enicepatide, a dual GLP-1/GIP receptor agonist, in patients with Type 2 Diabetes and overweight or obesity.

Clinical Trial Data

Phase

Phase II

Primary Endpoint

Met

Importance:7/10

Sentiment:

0.80

Phase 2GLP-1GIP receptor agonistType 2 DiabetesObesity

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on September 22, 2026 5:05 AM

Read Original